Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in CashFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Goldenwell Biotech (GWLL) Cash from Financing Activities (2019 - 2024)

Goldenwell Biotech filings provide 5 years of Cash from Financing Activities readings, the most recent being $70000.0 for Q4 2024.

  • On a quarterly basis, Cash from Financing Activities rose 15.92% to $70000.0 in Q4 2024 year-over-year; TTM through Sep 2025 was $67900.0, a 38.07% decrease, with the full-year FY2024 number at $119250.0, down 0.95% from a year prior.
  • Cash from Financing Activities hit $70000.0 in Q4 2024 for Goldenwell Biotech, up from -$2100.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $170125.0 in Q1 2021 to a low of -$2100.0 in Q3 2024.
  • Median Cash from Financing Activities over the past 4 years was $30000.0 (2023), compared with a mean of $53471.6.
  • Biggest five-year swings in Cash from Financing Activities: skyrocketed 2230.48% in 2021 and later plummeted 107.0% in 2024.
  • Goldenwell Biotech's Cash from Financing Activities stood at $1000.0 in 2020, then skyrocketed by 16912.5% to $170125.0 in 2021, then tumbled by 64.5% to $60388.0 in 2023, then rose by 15.92% to $70000.0 in 2024.
  • The last three reported values for Cash from Financing Activities were $70000.0 (Q4 2024), -$2100.0 (Q3 2024), and $49250.0 (Q2 2024) per Business Quant data.